Recombinant Human IL-28A/IFN-lambda 2 (HEK293) Protein

R&D Systems, part of Bio-Techne | Catalog # 8417-IL

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Carrier Free
8417-IL-025/CF
Catalog #
Availability
Size / Price
Qty
With Carrier
8417-IL-025
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

Q8IZJ0

Conjugate

Unconjugated

Applications

Bioactivity

View all IL-28A/IFN-lambda 2 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human IL-28A/IFN-lambda 2 protein
Val26-Val200

Purity

>95%, by SDS-PAGE with silver staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Val26 & Val28

Predicted Molecular Mass

20 kDa

SDS-PAGE

20-23 kDa, reducing condtions

Activity

Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63.
The ED50 for this effect is 5-25 ng/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 8417-IL
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 8417-IL/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-28A/IFN-lambda 2

IL‑28A (Interferon-lambda 2; IFN-lambda 2), IL-28B/IFN-lambda 3, and IL-29/IFN-lambda 1 are type III interferons which are distantly related to IL-10 family and type I IFN family cytokines (1‑3). Mature human IL-28A is an approximately 22-25 kDa protein that shares 66% amino acid (aa) sequence identity with mouse and rat IL-28A and shows cross-species activity (4). It shares 96% and 70% aa sequence identity with human IL-28B and IL-29, respectively. Type III interferons are upregulated in response to viral infection, and they act predominantly on epithelial cells through a receptor complex that contains IL-10 R beta and IL-28 R alpha/IFN-gamma R1 (4-6). Type III IFNs function as anti-viral molecules and induce the upregulation of MHC class I antigen (4, 5, 7). IL-28A promotes the Th1 polarization of dendritic cells in the airway (e.g. production of IL-12 p70 and IFN-gamma) and inhibits Th2 and Th17 mediated inflammation (8). In the liver, however, the IL-28A induced Th1 cytokine response contributes to inflammation in T cell mediated hepatitis (9). IL-28A additionally exhibits anti-tumor activity, in part by enhancing IL-12 dependent anti-tumor CTL responses in vivo (10-12). In contrast, it is up-regulated in invasive bladder cancer where it promotes tumor cell migration (13).

References

  1. Durbin, R.K. et al. (2013) Immunol. Rev. 255:25.
  2. Li, Q. et al. (2013) Front. Biosci. (Landmark Ed.) 18:909.
  3. Lopusna, K. et al. (2013) Acta Virol. 57:171.
  4. Ank, N. et al. (2006) J. Virol. 80:4501.
  5. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
  6. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.
  7. Pott, J. et al. (2011) Proc. Natl. Acad. Sci. USA 108:7944.
  8. Koltsida, O. et al. (2011) EMBO Mol. Med. 3:348.
  9. Siebler, J. et al. (2007) Gastroenterology 132:358.
  10. Sato, A. et al. (2006) J. Immunol. 176:7686.
  11. Tezuka, Y. et al. (2012) Lung Cancer 78:185.
  12. Numasaki, M. et al. (2007) J. Immunol. 178:5086.
  13. Lee, S.J. et al. (2012) PLoS ONE 7:e40267.

Long Name

Interleukin 28A

Alternate Names

IFN-lambda 2, IL28A

Entrez Gene IDs

282616 (Human)

Gene Symbol

IFNL2

UniProt

Q8IZJ0

Additional IL-28A/IFN-lambda 2 Products

Product Documents for Recombinant Human IL-28A/IFN-lambda 2 (HEK293) Protein

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS 8417-IL (with carrier)
Download SDS 8417-IL/CF (carrier free)

Product Specific Notices for Recombinant Human IL-28A/IFN-lambda 2 (HEK293) Protein

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.